Bayer, a leading pharmaceutical firm and Rad AI have declared a partnership to offer Rad AI’s advanced AI radiology operational solutions to calantic digital solution customers. In addition to Bayer's CalanticTM Digital Solutions platform, Rad...
Lupin Limited, a leading pharmaceutical firm, declared that it has secured a tentative endorsement from the US Food and Drug Administration (FDA) for its Abbreviated New Medication Application for olopatadine hydrochloride ophthalmic arrangement...
iRegene Therapeutics, an earliest biotech firm in the world focusing on correctly reprograming cell destiny and functions utilizing chemicals, On June 20, the US Food and Drug Administration (FDA) approved the IND application for NouvNeu001...
Verona Pharma plc, reports the US Food and Drug Administration ("FDA") approved Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (COPD) in grown-up patients. Since more than 20 years ago, Ohtuvayre is the first...
Silo Pharma, biopharmaceutical firm focused on in the formation of novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments declared that it has secured a agreement to its its contract research...
EG 427, a biotech firm that is leading the development of pinpoint DNA medicines for common neurology ailments using its unique non-replicative HSV-1 vector platform, announces that it gained Investigational New Drug (IND) authorization from the...
Evommune, Inc., a clinical-stage biotechnology firm based in Palo Alto that is exploring for new ways to treat immune-mediated inflammatory diseases, declared it has forayed into a definitive, worldwide license agreement with AprilBio Co., Ltd...
PharmaEssentia USA Corporation, a worldwide biopharmaceutical trailblazer situated in Taiwan utilizing profound mastery and demonstrated scientific principles to convey new biologics in hematology, oncology and immunology, declared completion of...
Roche, a leading Pharmaceutical firm, declared that the European Commission has given marketing authorisation for Ocrevus (ocrelizumab) subcutaneous (SC) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple...
Eli Lilly and Company has declared a collaboration with OpenAI, which will allow Lilly to use OpenAI's generative AI to develop novel antimicrobials for drug-resistant diseases. Antimicrobial resistance (AMR) is a major danger to public health...
, CDSCO.jpg)
